Dr. Liedert is currently working at Boehringer Ingelheim, prior to this he was holding a director position at Merck Serono, serving as Head of Immunopharmacology. He was member of the strategy implementation group, which established the Merck Serono´s Biosimilars Unit in 2012. He is now permanent member of the corporate Biosimilars Strategy and Policy Committee. In parallel, Dr. Liedert is intimately involved in Merck´s innovator program, especially in the field of monoclonal antibodies: His group drives promising biopharmaceutical compounds through the sensitive transition phase from First in Man to successful Proof of Concept trials and establishes concepts for corresponding companion diagnostics.
Dr. Liedert got insight experience of the Health Authorities´ perspective, when he worked as senior regulator at the Paul-Ehrlich-Institute (PEI), the German Federal Agency for biologics and at the EMA, where he represented Germany in the Safety Working Party. He was co-author of several guidelines, which focus on risk mitigation for early clinical trials, immunogenicity and comparability/biosimilarity exercises.